| Dr Mouhamad Mansour, MD | |
|
1300 Anne St Nw, Bemidji, MN 56601 | |
| (218) 333-5000 | |
| (218) 333-4961 |
| Full Name | Dr Mouhamad Mansour |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 16 Years |
| Location | 1300 Anne St Nw, Bemidji, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851523500 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Bemidji Medical Center | Bemidji, MN | Hospital |
| Sanford Bagley Medical Center | Bagley, MN | Hospital |
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Health Of Northern Minnesota | 5597725168 | 258 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.
Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP).
› Verified 4 days ago
| Entity Name | Sanford Health Of Northern Minnesota |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770849697 PECOS PAC ID: 5597725168 Enrollment ID: O20041025000442 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.
Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mouhamad Mansour, MD Po Box 2010, Fargo, ND 58122-2484 Ph: () - | Dr Mouhamad Mansour, MD 1300 Anne St Nw, Bemidji, MN 56601 Ph: (218) 333-5000 |
News Archive
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.
Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.
Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.
Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP).
› Verified 4 days ago
Rodney D Will, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1233 34th St Nw, Bemidji, MN 56601 Phone: 218-333-5000 Fax: 218-759-5024 | |
Calvin Tsogmo, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 Anne St Nw, Bemidji, MN 56601 Phone: 218-333-5000 | |
Dr. Mary Susanna Salter, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 514 Beltrami Ave Nw, Bemidji, MN 56601 Phone: 218-766-9281 | |
Dr. Hina Rahman, M.B.,B.S. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1233 34th St Nw, Bemidji, MN 56601 Phone: 218-333-5305 | |
Dr. John D Kolstoe, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 Anne St Nw, Bemidji, MN 56601 Phone: 218-333-6000 | |
Daniel Peter Dekrey, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1300 Anne St Nw, Bemidji, MN 56601 Phone: 218-333-5000 | |
Kirstin S Lesage, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1233 34th St Nw, Bemidji, MN 56601 Phone: 218-333-5522 |